@article{00dbbb4c3ea049faaa5e6560e9b15891,
title = "Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome",
abstract = "Background: Colchicine reduces risk of cardiovascular events in patients post–myocardial infarction and in patients with chronic coronary disease. It remains unclear whether this effect is related to the time of onset of treatment following an acute coronary syndrome (ACS). Objectives: This study investigates risk for major adverse cardiovascular events in relation to history and timing of prior ACS, to determine whether the benefits of colchicine are consistent independent of prior ACS status. Methods: The LoDoCo2 (Low-Dose Colchicine 2) trial randomly allocated patients with chronic coronary disease to colchicine 0.5 mg once daily or placebo. The rate of the composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization was compared between patients with no prior, recent (6-24 months), remote (2-7 years), or very remote (>7 years) ACS; interaction between ACS status and colchicine treatment effect was assessed. Results: In 5,522 randomized patients, risk of the primary endpoint was independent of prior ACS status. Colchicine consistently reduced the primary endpoint in patients with no prior ACS (incidence: 2.8 vs 3.4 events per 100 person-years; hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.52-1.27), recent ACS (incidence: 2.4 vs 3.3 events per 100 person-years; HR: 0.75; 95% CI: 0.51-1.10), remote ACS (incidence: 1.8 vs 3.2 events per 100 person-years, HR: 0.55; 95% CI: 0.37-0.82), and very remote ACS (incidence: 3.0 vs 4.3 events per 100 person-years, HR: 0.70; 95% CI: 0.51-0.96) (P for interaction = 0.59). Conclusions: The benefits of colchicine are consistent irrespective of history and timing of prior ACS. (The LoDoCo2 Trial: Low Dose Colchicine for secondary prevention of cardiovascular disease [LoDoCo2] ACTRN12614000093684)",
keywords = "anti-inflammatory agents, atherosclerosis, cardiovascular inflammation, ischemic risk, myocardial infarction, secondary prevention",
author = "{LoDoCo2 Trial Investigators} and Opstal, {Tjerk S.J.} and Fiolet, {Aernoud T.L.} and {van Broekhoven}, Amber and A. Mosterd and Eikelboom, {John W.} and Nidorf, {S. M.} and Thompson, {Peter L.} and Michiel Duyvendak and {van Eck}, {J. W.Martijn} and {van Beek}, {Eug{\`e}ne A.} and {den Hartog}, Frank and Budgeon, {Charley A.} and Bax, {Willem A.} and Tijssen, {Jan G.P.} and {El Messaoudi}, Saloua and Cornel, {J. H.} and Nidorf, {S. M.} and Xu, {X. F.} and Ireland, {M. A.} and D. Latchem and A. Whelan and R. Hendriks and P. Salkani and Tan, {I. W.} and Thompson, {A. G.} and Morton, {A. M.} and Hockings, {B. E.} and Thompson, {P. L.} and B. King and Cornel, {J. H.} and H. Bakker-Lohmeijer and A. Mosterd and P. Bunschoten and The, {S. H.K.} and {van der Kooi}, S. and T. Lenderink and Lardinois, {R. G.J.L.} and Hoogslag, {P. A.M.} and {de Vos}, A. and A. Jerzewski and S. Jansen and Nierop, {P. R.} and {van der Knaap}, M. and Swart, {H. P.} and R. Kingma and J. Schaap and Blom, {L. B.} and Kuijper, {A. F.M.} and E. Bayraktar-Verver and {van Hessen}, {M. W.J.} and Engelen, {W. C.T.C.} and {van Eck}, {J. W.M.} and {van der Ven-Elzebroek}, N. and {van Hal}, {J. M.C.} and Drost, {I. M.J.} and {den Hartog}, {F. R.} and {van Wijk}, D. and {van Beek}, E. and {van der Horst}, C. and Bartels, {G. L.} and M. Hendriks and {de Nooijer}, C. and C. Welten and E. Ronner and A. Dijkshoorn and Prins, {F. J.} and Rutten, {R. N.A.} and Beele, {D. P.W.} and I. Hendriks and {van der Sluis}, A. and Badings, {E. A.} and Westendorp, {I. C.D.} and A. Melein and R{\"o}mer, {Tj J.} and P. Bruines and {van de Wal}, R. and {Leenders - van Lieshout}, I. and Hemels, {M. E.W.} and K. Meinen-Werner and {de Groot}, {M. R.} and G. Post and Mulder, {M. W.C.} and S. Stuij and {van Nes}, E. and P. Luyten and J. Plomp and Veldmeijer, {S. V.} and Asselman, {M. J.} and Scholtus, {P. A.}",
year = "2021",
month = aug,
day = "31",
doi = "10.1016/j.jacc.2021.06.037",
language = "English",
volume = "78",
pages = "859--866",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Academic Press",
number = "9",
}
